Low expression of microRNA-204 (MIR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Butrym, Aleksandra ^a   Rybka, Justyna ^a   Baczyńska, Dagmara ^a   Tukiendorf, Andrzej ^b   Kuliczkowski, Kazimierz ^a   Mazur, Grzegorz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Acute myeloid leukemia; Expression; MIR 204; Prognosis; Survival

Indexed keywords

MICRORNA; MICRORNA 204; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; ACUTE MYELOID LEUKEMIA; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937510430     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0184-z     Document Type: Article

References (24)

1. Ustun C, Marcucci G. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. Curr Opin Hematol. 2015;22:85-91.
2. Estey EH. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol. 2014;89:1063-81.
3. Chen Z, Sangwan V, Banerjee S, Mackenzie T, Dudeja V, Li X, Wang H et al. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer. 2013;12:105. doi: 10.1371/journal.pone.0052397.
4. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010;20:589-99.
5. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, et al. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One. 2012;7(12), e52397. doi: 10.1371/journal.pone.0052397.
6. Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, et al. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 2015;34:35.
7. Yu G, Yao W, Xiao W, Xu H, Li H, Lang B. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res. 2014;33:779.
8. Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.
9. Sümbül AT, Göʇebakan B, Ergün S, Yengil E, Batmacl CY, Tonyall Ö, et al. miR-204-5p expression in colorectal cancer: an autophagy-associated gene. Tumour Biol. 2014;35:12713-9.
10. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-9.
11. Cox DR. Regression models and life-tables. J Royal Stat Soc B. 1972;34:187-220.
12. Congdon P. Applied Bayesian modelling. Chichester: Wiley; 2003. p. 118-26.
13. R Core Team. R: A language and environment for statistical computing. Version 3.0.3. 2014 Vienna: R Foundation for Statistical Computing, http://www.r-project.org/ ]
14. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS. Version 1.4.3. 2003. Cambridge: Imperial College School of Medicine & Medical Research Council-Biostatistics Unit, www.mrc-bsu.cam.ac.uk/bugs/winbugs/).
15. Weng H, Lal K, Yang FF, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015;S2210-7762(14):00288-9. doi: 10.1016/j.cancergen.2014.12.006.
16. Butrym A, Rybka J, Baczyńska D, Tukiendorf A, Kuliczkowski K, Mazur G. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med. 2015;26:1-8.
17. Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L. Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014;7:3287-92.
18. Xia Y, Zhu Y, Ma T, Pan C, Wang J, He Z, et al. miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC. FEBS Lett. 2014;588:3703-12. doi: 10.1016/j.febslet.2014.08.016.
19. Wang T, Li F, Tang S. MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncol Lett. 2015;9:967-71.
20. Todorova K, Metodiev MV, Metodieva G, Zasheva D, Mincheff M, Hayrabedyan S. miR-204 is Dysregulated in Metastatic Prostate Cancer In Vitro. Mol Carcinog. 2015; doi: 10.1002/mc.22263
21. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012;107:967-76.
22. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012;130:1036-345.
23. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc natl Acad Sci USA. 2008;105:3945-50.
24. Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, et al. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 2013;12:990-9.